OTCPK:UDRG.Y

Stock Analysis Report

Executive Summary

UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally.

Snowflake

Fundamentals

Flawless balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has UDG Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:UDRG.Y

1.3%

US Healthcare

1.2%

US Market


1 Year Return

n/a

OTCPK:UDRG.Y

-8.2%

US Healthcare

1.7%

US Market

No trading data on UDRG.Y.

No trading data on UDRG.Y.


Share holder returns

UDRG.YIndustryMarket
7 Day0%1.3%1.2%
30 Day0%-0.7%4.9%
90 Dayn/a0.01%3.7%
1 Yearn/a-6.8%-8.2%3.9%1.7%
3 Yearn/a30.1%24.9%47.2%37.7%
5 Yearn/a63.5%53.8%60.0%42.4%

Price Volatility Vs. Market

How volatile is UDG Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is UDG Healthcare undervalued based on future cash flows and its price relative to the stock market?

541.46x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

UDG Healthcare's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

UDG Healthcare's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

UDG Healthcare is overvalued based on earnings compared to the US Healthcare industry average.

UDG Healthcare is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

UDG Healthcare is poor value based on expected growth next year.


Price Based on Value of Assets

UDG Healthcare is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is UDG Healthcare expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

29.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

UDG Healthcare's revenue is expected to grow by 4.4% yearly, however this is not considered high growth (20% yearly).

UDG Healthcare's earnings are expected to grow significantly at over 20% yearly.

UDG Healthcare's revenue growth is positive but not above the United States of America market average.

UDG Healthcare's earnings growth is expected to exceed the United States of America market average.

UDG Healthcare's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

UDG Healthcare is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has UDG Healthcare performed over the past 5 years?

-10.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

UDG Healthcare's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

UDG Healthcare's 1-year earnings growth is negative, it can't be compared to the 5-year average.

UDG Healthcare's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.


Return on Equity

UDG Healthcare has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

UDG Healthcare used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

UDG Healthcare has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is UDG Healthcare's financial position?


Financial Position Analysis

UDG Healthcare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

UDG Healthcare's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

UDG Healthcare's level of debt (27.5%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (98.8% vs 27.5% today).

Debt is well covered by operating cash flow (42.1%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 14.8x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.3x debt.


Next Steps

Dividend

What is UDG Healthcare's current dividend yield, its reliability and sustainability?

2.34%

Expected Dividend Yield


Dividend Yield and Payments Analysis

UDG Healthcare's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.41%).

UDG Healthcare's dividend is below the markets top 25% of dividend payers in United States of America (3.64%).

Whilst dividend payments have been stable, UDG Healthcare has been paying a dividend for less than 10 years.

Dividend payments have increased, but UDG Healthcare only paid a dividend in the past 9 years.


Current Payout to Shareholders

Dividends paid are not well covered by earnings (0.1x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (3x coverage).


Next Steps

Management

What is the CEO of UDG Healthcare's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Brendan McAtamney (55yo)

3.2yrs

Tenure

US$1,995,000

Compensation

Mr. Brendan McAtamney has been the Chief Executive Officer of UDG Healthcare plc since February 2, 2016 and has been an Executive Director since December 16, 2013. Mr. McAtamney has been a Non-Executive Di ...


CEO Compensation Analysis

Brendan's remuneration is lower than average for companies of similar size in United States of America.

Brendan's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.6yrs

Average Tenure

48yo

Average Age

The tenure for the UDG Healthcare management team is about average.


Board Age and Tenure

4.1yrs

Average Tenure

59yo

Average Age

The tenure for the UDG Healthcare board of directors is about average.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Liam Logue

    Executive Vice President of Corporate Development

    • Tenure: 5.5yrs
  • Nigel Clerkin (44yo)

    CFO & Executive Director

    • Tenure: 0.9yrs
    • Compensation: US$574.20k
  • Julian Tompkins

    President of Ashfield Commercial & Clinical

    • Tenure: 0yrs
  • Eimear Kenny (48yo)

    Group Head of Human Resources

    • Tenure: 0yrs
  • Mike O'Hara

    MD & President of Sharp Packaging

    • Tenure: 0yrs
  • Brendan McAtamney (55yo)

    CEO & Executive Director

    • Tenure: 3.2yrs
    • Compensation: US$2.00m
  • Eleanor Garvey

    Group Head of Quality & Compliance

    • Tenure: 0yrs
  • Keith Byrne

    Head of Investor Relations

    • Tenure: 0yrs
  • Damien Moynagh

    General Counsel & Company Secretary

    • Tenure: 0yrs
  • Tom Mitchell

    Uk Head of Syndicated Services for Ashfield

    • Tenure: 2yrs

Board Members

  • Linda Wilding (59yo)

    Non-Executive Director

    • Tenure: 5.3yrs
    • Compensation: US$84.00k
  • Peter Gray (63yo)

    Chairman of the Board

    • Tenure: 7.2yrs
    • Compensation: US$208.00k
  • Myles Lee (65yo)

    Non-Executive Director

    • Tenure: 2yrs
    • Compensation: US$82.00k
  • Chris Corbin (63yo)

    Non-Executive Director

    • Tenure: 15.8yrs
    • Compensation: US$1.05m
  • Nigel Clerkin (44yo)

    CFO & Executive Director

    • Tenure: 0.9yrs
    • Compensation: US$574.20k
  • Lisa Ricciardi (58yo)

    Non-Executive Director

    • Tenure: 5.8yrs
    • Compensation: US$68.00k
  • Chris Brinsmead (59yo)

    Senior Independent Non-Executive Director

    • Tenure: 1.8yrs
    • Compensation: US$94.00k
  • Brendan McAtamney (55yo)

    CEO & Executive Director

    • Tenure: 3.2yrs
    • Compensation: US$2.00m
  • Nancy Miller-Rich (59yo)

    Non-Executive Director

    • Tenure: 2.8yrs
    • Compensation: US$68.00k
  • Erik Van Snippenberg (54yo)

    Non-Executive Director

    • Tenure: 0.8yrs
    • Compensation: US$17.00k

Company Information

UDG Healthcare plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: UDG Healthcare plc
  • Ticker: UDRG.Y
  • Exchange: OTCPK
  • Founded: 1948
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: UK£1.591b
  • Listing Market Cap: UK£2.057b
  • Shares outstanding: 248.82m
  • Website: https://www.udghealthcare.com

Number of Employees


Location

  • UDG Healthcare plc
  • 20 Riverwalk
  • Citywest Business Campus
  • Dublin
  • Co. Dublin
  • 24
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UDGLSE (London Stock Exchange)YesOrdinary SharesGBGBPJan 1992
UDHC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
UN6ADB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
UDGLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPJan 1992
UDRG.YOTCPK (Pink Sheets LLC)ADRUSUSDOct 2008

Biography

UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and interna ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/04/28 00:23
End of Day Share Price2019/01/29 00:00
Earnings2018/09/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.